Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Celles-ci privilégieraient l’hypothèse d’une fuite d’un laboratoire chinois, avec une probabilité de 80 à 95 pour cent. L’article raconte comment le service fédéral de renseignement ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...

Les laboratoires pharmaceutiques saisissent la justice européenne sur le traitement des eaux usées La directive européenne sur le traitement des eaux urbaines résiduaires impose aux industries ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy, to ...

Ces personnes effectuent des tests courants de laboratoire médical. Elles assurent la validité technique des résultats à des fins de diagnostic ou de recherche. Ces tests incluent entre autres des ...